Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical glaucoma medications and diurnal intraocular pressure variability
ACTRN12618001025224Phase 4Completed
- Sponsor
- Dr. Barbara Zangerl
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of latanoprost and timolol in Glaucoma and ocular hypertension (2 arms), sponsored by Dr. Barbara Zangerl. Primary endpoints: Mean intraocular pressure during intervention versus control and Variance of intraocular pressure during intervention versus control. Started Aug 2018; status: completed.
02
Drugs
latanoprosttimolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on ACTRN12618001025224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001025224.